Zwitterionic-Coated PDMS Bulking Agent for Low-Inflammation Injection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bulking agents for sphincter-related diseases like urinary and fecal incontinence cause inflammatory responses and require additional injections due to material migration, lacking durability and safety for long-term use.
Innovation Solution
A bulking agent comprising polydimethylsiloxane (PDMS) particles coated with a zwitterionic polymer, mixed with a viscous second composition, inhibits inflammatory responses and maintains volume over time.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional bulking agents (silicone, pyrolytic carbon-coated ceramic beads, autologous fat, etc.) are injected into the anal sphincter, then the bulking effect is achieved, but inflammatory responses occur and additional injections are required due to material migration
Solution Approach 1:
The patent uses a composite material consisting of polydimethylsiloxane particles coated with a zwitterionic polymer. This composite structure combines the bulking properties of PDMS with the anti-inflammatory and biocompatible characteristics of the zwitterionic polymer layer, resolving the contradiction between achieving durable bulking effect and avoiding inflammatory responses.
Solution Approach 2:
The patent changes the surface chemical parameters of the PDMS particles by coating them with a zwitterionic polymer. This parameter change transforms the surface properties from inflammatory-inducing to anti-inflammatory, while maintaining the core bulking function of the PDMS particles.
2Reliability
If conventional bulking agents are injected, then initial bulking effect is achieved, but material migration occurs requiring reoperation
Solution Approach 1:
The zwitterionic polymer coating on PDMS particles creates a composite material with improved stability. The polymer layer prevents material migration while maintaining the bulking effect, ensuring long-term safety and position stability without requiring reoperation.
3Ease of manufacture
If existing bulking agents are used, then treatment can be performed, but they are expensive and require additional injection due to material movement
Solution Approach 1:
The patent modifies the surface parameters of PDMS particles through zwitterionic polymer coating, creating a cost-effective solution that maintains long-lasting bulking effect without the need for expensive conventional agents or additional injection procedures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The agent provides a biocompatible bulking effect, reducing inflammatory responses and maintaining volume, suitable for sphincter-related diseases and cosmetic procedures.
Implementation Method 1
the zwitterionic polymer of the first composition has a surfactant property
Data Source
Figure 1
Figure 2(a)~2(b)
Figure 3
AI summary
The present invention relates to an in-vivo bulking agent which can be used as a medicinal agent for prevention or treatment of at least one disease selected from the group consisting of urinary incontinence, fecal incontinence, and gastroesophageal reflux or as a filler for use in a plastic surgery procedure, and to a preparation method therefor. The in-vivo bulking agent can exhibit a bulking effect when injected into the body and particularly, is highly biocompatible because a first composition in which silicone particles are coated with a zwitterionic polymer having a surfactant property is introduced into a second composition, whereby the bulking agent can inhibit inflammatory reactions in vivo.